Diagnosis, Characterization and Treatment of Emerging Pathogens, Second Edition

A special issue of Microorganisms (ISSN 2076-2607). This special issue belongs to the section "Public Health Microbiology".

Deadline for manuscript submissions: 31 August 2024 | Viewed by 1074

Special Issue Editor


E-Mail Website
Guest Editor
Biodesign Institute, Arizona State University, Tempe, AZ, USA
Interests: emerging pathogens; diagnosis; viral infection; inhibitor; treatment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue is the continuation of our previous Special Issue, entitled “Diagnosis, Characterization and Treatment of Emerging Pathogens”.

Emerging infectious diseases are perhaps the most rapidly spreading diseases. SARS-CoV-2 has infected 556 million people and caused more than 6 million deaths worldwide. To date, the effects of this virus are still resonating worldwide. Recently, the monkeypox virus emerged and spread to more than 30 countries over the course of about one month. Concurrently, many other pathogens have emerged, including malaria, Zika virus, dengue, Ebola, West Nile virus, and diarrheagenic E. coli, all of which threaten the health of billions of people worldwide. To help in the fight against these emerging infectious diseases, we aim to collect manuscripts focusing on emerging pathogens, including viruses, bacteria, protozoa, and fungi. 

The areas of interest could include, but are not limited to, the following:

  • Novel methods and strategies for the early detection of emerging pathogens;
  • The characterization of specific genes or protein targets for the detection or treatment of emerging pathogens;
  • Novel agents to inhibit emerging pathogens.

Dr. Shengxi Chen
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Microorganisms is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • emerging pathogens
  • detection
  • characterization treatment
  • infectious diseases
  • viruses
  • bacteria
  • protozoa
  • fungi

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1728 KiB  
Article
Emergence of Recombinant Subclade D3/Y in Coxsackievirus A6 Strains in Hand-Foot-and-Mouth Disease (HFMD) Outbreak in India, 2022
by Sanjaykumar Tikute, Pratik Deshmukh, Nutan Chavan, Anita Shete, Pooja Shinde, Pragya Yadav and Mallika Lavania
Microorganisms 2024, 12(3), 490; https://doi.org/10.3390/microorganisms12030490 - 28 Feb 2024
Viewed by 856
Abstract
Coxsackievirus-A6 (CV-A6) is responsible for more severe dermatological manifestations compared to other enteroviruses such as CV-A10, CV-A16, and EV-A71, causing HFMD in children and adults. Between 2005 and 2007, the recombinant subclade D3/RF-A started to expand globally, and a CV-A6 pandemic started. The [...] Read more.
Coxsackievirus-A6 (CV-A6) is responsible for more severe dermatological manifestations compared to other enteroviruses such as CV-A10, CV-A16, and EV-A71, causing HFMD in children and adults. Between 2005 and 2007, the recombinant subclade D3/RF-A started to expand globally, and a CV-A6 pandemic started. The study aimed to conduct whole-genome sequencing (WGS) of an isolated CV-A6 strain from currently circulating HFMD cases from India in 2022. Gene-specific RT-PCR and sequencing were used to perform molecular characterization of the isolated virus. Confirmation of these isolates was also performed by transmission electron microscopy and WGS. Among eleven positive clinical enterovirus specimens, eight CV-A6 strains were successfully isolated in the RD cell line. Isolates confirmed the presence of the CV-A6 strain based on VP1 and VP2 gene-specific RT-PCR. Sequences of isolates were clustered and identified as the novel CV-A6 strain of the D3/Y sub-genotype in India. The studies revealed that the D3/Y sub-genotype is being introduced into Indian circulation. The predicted putative functional loops found in VP1 of CV-A6 showed that the nucleotide sequences of the amino acid were a remarkably conserved loop prediction compatible with neutralizing linear epitopes. Therefore, this strain represents a potential candidate for vaccine development and antiviral studies. Full article
Show Figures

Figure 1

Back to TopTop